Ozempic, Zepbound and weight loss
Buyer beware: Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.
Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback